Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02318914 · ClinicalTrials.gov registry record · Phase 3
A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum
A Phase 3 study, sponsored by Xoma (US).
- Terminated
- Registry status
- Phase 3
- Development phase
- 15
- Enrollment target
NCT02318914: Clinical Trial Phase 3 study, sponsored by Xoma (US).
NCT02318914 is a Phase 3 study that was terminated before completion, run by Xoma (US). The registered enrollment target is 15 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02318914, a Phase 3 study, was terminated before completion, sponsored by Xoma (US).
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 15 participants
- Enrollment target
Study Summary
The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
Interventions
- DRUG gevokizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-11 |
| Est. Completion | 2016-02 |
| Phase | Phase 3 |
Why NCT02318914 stopped before completion
NCT02318914 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which gevokizumab is the first listed.
NCT02318914 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02318914 about?
NCT02318914 is a clinical study titled "A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum". The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers
What is the current status of trial NCT02318914?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 15 participants. The study started on 2014-11. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02318914?
The interventions under investigation include: gevokizumab (DRUG).
Who is sponsoring clinical trial NCT02318914?
This trial is sponsored by Xoma (US), which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02318914's enrollment target sits among peer trials
15 1977th of 2000 higher than 18 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia